Kohjin Bio KBM551 (IL-2 Depleted Culture medium for human T cell activation and expansion)

KBM551 is a medium suitable for both activated and expanded cultures of human peripheral blood T cells stimulated with solid-phase anti-CD3 antibody

Add to cart

KBM 551 is a specialized cell culture medium designed to support the activation and expansion of human peripheral blood T cells.

This versatile medium provides an optimal environment for T-cell proliferation.

Key Features:

T cell-specific: Tailored for the culture of activated and expanded T cells.
IL-2-free: Requires the addition of exogenous IL-2 for optimal growth.
Enhanced buffering: Maintains stable pH for optimal cell culture conditions.
Antibiotic-free: Can be supplemented with desired antibiotics as needed.

Recommended Applications:

T cell research: Studying T cell function and activation.
Immunotherapy: Developing T cell-based therapies for various diseases.

Reference Publications

Nishi, K., Ishikura, S., Umebayashi, M., Morisaki, T., Inozume, T., Kinugasa, T., Aoki, M., Nimura, S., Swain, A., Yoshida, Y., Hasegawa, S., Nabeshima, K., Sakata, T., Shirasawa, S., & Tsunoda, T.

Mutant KRAS promotes NKG2D+ T cell infiltration and CD155 dependent immune evasion.

Anticancer Research, 40(8), 4663–4674. (2020).

DOI: https://doi.org/10.21873/anticanres.14465

Article Snippet: “Generation of cytokine-activated killer cells. PBMCs were activated in KBM551 medium (Kohjin Bio, Saitama, Japan) supplemented with 5% human serum, 2000 U/ml penicillin, 10 μg/ml streptomycin, 2000 U/ml recombinant human interleukin-2 (IL-2), and 0.5% albumin (Nihon Pharmaceutical Co., Ltd., Tokyo, Japan) in T-75 flasks coated with 2 μg/ml anti-CD3 monoclonal antibody (OKT3, Janssen Pharmaceutical K.K., Tokyo, Japan).”

Kim, A., Lee, KG., Kwon, Y. et al.

Off-the-Shelf, Immune-Compatible Human Embryonic Stem Cells Generated Via CRISPR-Mediated Genome Editing.

Stem Cell Rev and Rep 17, 1053–1067 (2021).

DOI: https://doi.org/10.1007/s12015-020-10113-7

Article Snippet: “To expand activated T cells, PBMCs were added to flasks pre-coated with anti-CD3 (1:500, Clone OKT-3, Invitrogen) and anti-CD28 (1:500, Clone CD28.2, Invitrogen) monoclonal antibodies and then incubated in serum-free KBM551 medium (Kohjin Bio) containing 200 IU/ml human recombinant interleukin-2 (rhIL-2) (R&D Systems) at 37 °C in a 5% CO₂ atmosphere.”